Pharmacological treatments such as metformin, sodium glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists are generally effective and well-tolerated, and have significantly contributed to improving glycemic control and preventing complications in T2DM [5]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.